FMP
ProKidney Corp.
PROK
NASDAQ
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
0.854 USD
-0.0316 (-3.7%)
Historical Prices
From:
To:
About
ceo
Dr. Bruce Culleton M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.prokidney.comexchange
NASDAQ
Description
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
CIK
0001850270
ISIN
KYG7S53R1049
CUSIP
N/A
Address
2000 Frontis Plaza Blvd.
Phone
336 999 7028
Country
US
Employee
204
IPO Date
Jun 30, 2021
Financial Statement
Earnings
PROK Financial Summary
CIK
0001850270
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
KYG7S53R1049
Country
US
Price
0.85
Beta
1.59
Volume Avg.
771.17k
Market Cap
249.96M
Shares
-
52-Week
0.46-4.44
DCF
0.98
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.38
P/B
-
Website
https://www.prokidney.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest PROK News
zacks.com
Mar 21, 2025
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip ...
PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
globenewswire.com
Mar 17, 2025
ProKidney Reports Full Year 2024 Financial Results and Busin...
WINSTON-SALEM, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results and business highlights for the year ended December 31, 2024.
prnewswire.com
Jan 31, 2025
Kuehn Law Encourages Investors of ProKidney Corp. to Contact...
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
seekingalpha.com
Jan 31, 2025
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD...
Rilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as well as the potential confirmation about a “surrogate” endpoint for its Phase 3 trials. Currently, Rilparencel's Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that's suitable for the FDA.
globenewswire.com
Nov 26, 2024
ProKidney to Participate in Two Upcoming Conferences: Everco...
WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December:
globenewswire.com
Nov 12, 2024
ProKidney Reports Third Quarter 2024 Financial Results along...
WINSTON-SALEM, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2024, and gave several regulatory and clinical development updates.
globenewswire.com
Nov 5, 2024
ProKidney to Participate in the Guggenheim Inaugural Healthc...
WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in two upcoming healthcare conferences in November.
globenewswire.com
Oct 14, 2024
ProKidney Announces Five Abstracts Selected for Presentation...
WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA.
